| Business Summary | | Medicis
Pharmaceutical
is
a
specialty
pharmaceutical
company
and
an
independent
pharmaceutical
company
in
the
United
States
focusing
primarily
on
the
treatment
of
dermatological
conditions.
The
Company
offers
prescription
products
and
an
over-the-counter
(OTC)
product.
Medicis
develops
and
markets
products
for
major
segments
within
dermatology,
including
acne,
rosacea,
antifungals,
eczema,
hyperpigmentation,
pediculosis
(head
lice),
psoriasis,
seborrheic
dermatitis
and
cosmesis
(improvement
in
the
texture
and
appearance
of
skin).
The
Company's
primary
products
include
the
prescription
brands
Dynacin
(minocycline
HCl),
Triza
(benzoyl
peroxide),
Loprox
(ciclopirox),
Lustra
and
Lustra-AF
(hydroquinone),
Ovide
(malathion),
Plexion
(sodium
sulfacetamide/sulfur),
Lidex
(fluocinonide),
Synalar
(fluocinolone
acetonide),
Topicort
(desoximetasone),
Buphenyl
(sodium
phenylbutyrate),
a
prescription
product
indicated
in
the
treatment
of
Urea
Cycle
Disorder,
and
the
OTC
brand
Esoterica. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Medicis
is
an
independent
pharmaceutical
company
that
offers
prescription
and
over-the-counter
products
to
treat
a
number
of
dermatological
conditions.
For
the
fiscal
year
ended
6/30/01,
net
sales
increased
21%
to
$167.8
million.
Net
income
decreased
6%
to
$40.4
million.
Revenues
reflect
higher
sales
of
DYNACIN(R),
TRIAZ(R)
and
PLEXION(R).
Earnings
were
offset
by
a
$17.8
million
special
charge
for
a
research
and
development
collaboration
with
Corixa
Corp. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Jonah Shacknai, 43 Chairman,
CEO | $1.0M | $10M | Mark Prygocki, Sr., 34 CFO,
Exec. VP, Treasurer, Sec. | 480K | 62K | Richard Havens Exec.
VP of Sales and Marketing | -- | -- | Joseph Cooper Exec.
VP, Bus. Devel. | -- | -- | Mitchell Wortzman, Ph.D. Exec.
VP, R&D | -- | -- | Dollar
amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|